Skip to main content

Table 2 CYP3A4 and CYP3A5 genotypes in digestive cancer patients and healthy control individuals.

From: Genetic variability in CYP3A4 and CYP3A5in primary liver, gastric and colorectal cancer patients

CYP3A4 CYP3A5 Liver cancer
N (Frequency; 95% C.I.)
Stomach cancer
N (Frequency; 95% C.I.)
Colorectal cancer
N (Frequency; 95% C.I.)
Control subjects
N (Frequency; 95% C.I.)
*1A/*1A *3/*3 144 (80.9; 75.1–86.7) 74 (90.2; 83.8–96.7) 121 (80.1; 73.8–86.5) 134 (82.2; 76.4–88.1)
*1A/*1A *1/*3 17 (9.6; 5.2–13.9) 2 (2.4; 0–5.8) 18 (11.9; 6.8–17.1) 14 (8.6; 4.3–12.9)
*1A/*1A *1/*1 0 0 0 1 (0.6; 0–1.8)
*1A/*1B *3/*3 5 (2.8; 0.4–5.2) 1 (1.2; 0–3.6) 5 (3.3; 0.5–6.2) 1 (0.6; 0–1.8)
*1A/*1B *1/*3 12 (6.7; 3.1–10.4) 5 (6.1; 0.9–11.3) 6 (4.0; 0.9–7.1) 12 (7.4; 3.3–11.4)
*1A/*1B *1/*1 0 0 0 1 (0.6; 0–1.8)
*1B/*1B *1/*3 0 0 1 (0.7; 0–2.0) 0